Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2021 08:00 ET | Source: Genmab A/S

Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration

Media Release Collaboration to discover and evaluate novel product concepts based on the combination of Genmab’s antibodies and bispecific antibody technologies with Bolt’s proprietary...
June 01, 2021 06:27 ET | Source: Genmab A/S

Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference

Media ReleaseCopenhagen, Denmark, June 1, 2021Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer, Anthony Pagano and Chief Development Officer, Judith Klimovsky, will...
May 31, 2021 04:30 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; May 31, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
May 25, 2021 03:57 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; May 25, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
May 21, 2021 15:03 ET | Source: Genmab A/S

Genmab Announces that Janssen has been Granted U.S. FDA Approval for RYBREVANT™ (amivantamab-vmjw) for Patients with Metastatic Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations

Media ReleaseCopenhagen, Denmark, May 21, 2021 Janssen Biotech, Inc. (Janssen) received U.S. FDA approval for RYBREVANT™ (amivantamab-vmjw) for patients with metastatic non-small cell lung cancer...
May 21, 2021 09:08 ET | Source: Genmab A/S

Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Company Announcement Janssen received a positive CHMP opinion for DARZALEX® SC (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide and dexamethasone for the...
May 20, 2021 20:14 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; May 21, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
May 19, 2021 17:01 ET | Source: Genmab A/S

Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Media Release Copenhagen, Denmark, May 19, 2021 Poster presentations highlighting clinical data for investigational bispecific antibody epcoritamab (DuoBody®-CD3xCD20) at ASCO and EHAPhase 3...
May 19, 2021 06:41 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; May 19, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
May 17, 2021 04:34 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; May 17, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...